Growth differentiation factor-11

• US 7,384,753 B2
• Filed: 06/10/2003
• Issued: 06/10/2008
• Est. Priority Date: 07/08/1994
• Status: Expired due to Fees

• Current Assignee: Johns Hopkins University
• Original Assignee: Johns Hopkins University
• Inventors: McPherron, Alexandra C., Lee, Se-Jin
• Primary Examiner(s): Kemmerer; Elizabeth C.
• Assistant Examiner(s): XIE, XIAOZHEN
• Application Number:
  US10/459,127
• Publication Number:
  US 20040088747A1
• Time in Patent Office: 1,827 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: A01K 2207/05 Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/02 Animal zootechnically ameliorated
• CPC Class Codes: A01K 67/0276 Knock-out vertebrates
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12N 15/8509 for producing genetically modified animals, e.g. transgenic
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/111 spanning the whole gene, or a large part of it

Abstract

Growth differentiation factor-11 (GDF-11) is disclosed along with its polynucleotide sequence and amino acid sequence. The invention provides a method for identifying a compound that affects GDF-11 activity or gene expression.

Claims

1. A method for identifying a compound that affects GDF-11 activity or gene expression, comprising:

a) incubating the compound with a human GDF-11 polypeptide as set forth in SEQ ID NO;

2, or with a recombinant cell expressing a human GDF-11 as set forth in SEQ ID NO;

2 under conditions sufficient to allow the components to interact; and

b) determining the effect of the compound on GDF-11 activity or expression.

2. The method of claim 1, wherein the effect is inhibition of GDF-11 activity or expression.

3. The method of claim 2, wherein the effect is determined by comparing expression of GDF-11 prior to incubating with the compound with the expression of GDF-11 after incubating with the compound.

4. The method of claim 2, wherein the effect is measured by Northern Blot analysis.

5. The method of claim 2, wherein the effect is measured by Western Blot analysis.

6. The method of claim 2, wherein the effect is measured by muscle fiber analysis.

7. The method of claim 2, wherein the components interact in solution.

8. The method of claim 2, wherein the components interact in solid phase.

9. The method of claim 2, wherein the components interact in a cell.

10. The method of claim 2, wherein the compound is a member of a combinatorial library.